Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy ...



prognosis for stage 3 non small cell lung cancer :: Article Creator

Lung Cancer News From 2023

CURE® highlights some of the most significant lung cancer news of 2023 in honor of Lung Cancer Awareness Month.

In honor of November being Lung Cancer Awareness Month, here is a look back at some of the most impactful developments in the space from 2023.

Approval of Braftovi with Mektovi Adds to Targeted Options for Metastatic NSCLC

The Food and Drug Administration (FDA) recently approved Braftovi (encorafenib) with the combination of Mektovi (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). This FDA approval became the latest development as a targeted therapy to treat patients with lung cancer.

"It's just one more in a series of approvals of targeted therapies in lung cancer, which is a story that dates back now for about 15 years (which) is when this originally started," Dr. Gene G. Finley, assistant professor at Drexel University of College of Medicine and medical oncologist at AHN Cancer Institute, Allegheny Clinic Medical Oncology, said.

The most recent approval was based off the PHAROS trial, which, published in the Journal of Clinical Oncology, stated that "for patients with treatment-naïve and previously treated BRAF V600E-mutant metastatic NSCLC, (Braftovi) plus (Mektovi) showed a meaningful clinical benefit with a safety profile consistent with that observed in the approved indication in melanoma."

Trodelvy May Provide Benefits in Extensive-Stage Small Cell Lung Cancer

Trodelvy (sacituzumab govitecan-hziy) led to clinical benefit when used as second line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), according to part of a phase 2 trial that was shared at the 2023 ESMO Congress.

The study focuses on 30 patients, all of which received a partial response within the study. "Seventy-seven percent of patients (who underwent) post-baseline tumor assessment (experienced) some kind of tumor reduction, and 43% had a reduction of greater than 30%," lead study author Dr. Afshin Dowlati said in a presentation of the data. "Very few patients had up-front (disease) progression on their first imaging."

Trodelvy is now being investigated for the treatment of solid tumors in a TROPiCS-03 study, where about 40 patients plan to be enrolled in, while taking doses of Trodelvy.

"These results are encouraging in (patients with) ES-SCLC. The trial is ongoing, and we will hopefully have full results early (in 2024) with a full cohort. We believe that further investigation of (Trodelvy) in SCLC is warranted," Dowlati concluded.

Anamorelin Improves Weight Gain in Patients with Lung Cancer Experiencing Cachexia

Anamorelin improved weight gain for patients with non-small cell lung cancer (NSCLC) with cachexia over a placebo. These results were found within trials ANAM 17-20 and ANAM-17-21, presented at the 2023 ESMO Annual Congress.

A total of 318 patients were enrolled in each study, which investigated if the placebo group or anamorelin group experienced more weight gain improvement. Efficiency and safety of anamorelin was also investigated within the study.

"As an oral medication, it is convenient for patients and because of its longer half-life life, it can be given once daily," David Currow, deputy vice chancellor, University of Wollongong in Australia,explained during a presentation of the data. Anamorelin was favored over the placebo based on age, degree of weight loss, stage of disease, functional status and whether they underwent treatment with chemotherapy or immunotherapy.

Both trials showed that weight gain had improved within the anamorelin group of patients and remained consistent in comparison to the placebo group.

Jemperli Plus Chemo Continues to Demonstrate Strong Outcomes in Advanced NSCLC

When being treated with Jemperli (dostarlimab-gxly) plus chemotheraphy, patients with treatment-naïve, nonsquamous non-small cell lung cancer (NSCLC) experienced a higher objective response rate (ORR; patients who disease had responded to the treatment given) and overall survival improvements compared to Keytruda (pembrolizumab) combined with chemotherapy. These results were shown at the 2023 ESMO Congress.

"Results are consistent with the study hypothesis that (Jemperli) and (Keytruda) have similar efficacy," Dr. Solange Peters, ESMO past president, full professor and chair of medical oncology and the thoracic malignancies program in the department of oncology at the University Hospital of Lausanne in Switzerland, said in a presentation of the data. "…These results support further investigation of (Jemperli) as a treatment backbone in combination with standard-of-care treatments and future novel cancer therapies in patients with NSCLC."

These findings supported the examination of Jemperli and an upcoming 2 GALAXIES LUNG-201 study will be focusing on the safety, efficiency pharmacokinetics and pharmacodynamics of novel immunotherapy combinations versus single-agent immunotherapy drugs in patients with NSCLC, with Jemperli being one of them.

Rybrevant Plus Chemo Offers Better Progression-Free Survival for NSCLC Subset

Rybrevant (amivantamab-vmjw) combined with chemotherapy showed improved progression-free survival (PFS; time of started treatment until death or disease worsening) in patients with advanced EGFR exon 20 insertion-positive non-small cell lung cancer in comparison with chemotherapy treatment alone. These findings come from a phase 3 trial explained at the 2023 ESMO Congress.

A total of 308 patients were enrolled into the phase 3 trial, with 153 patients in the chemotherapy combined with Rybrevant group, and 155 in the chemotherapy group.

"Consistent PFS benefit (was seen) across predefined subgroups by blinded independent central review. (Rybrevant)-chemotherapy represents the new standard of care for first-line EGFR exon 20 insertion-mutated advanced NSCLC," Dr. Nicolas Girard, professor of respiratory medicine at Versailles Saint Quentin University and professor and head of the Curie-Montsouris Thorax Institute at the Institut Curie in France, said in the presentation that revealed the study's data.

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.


Osimertinib + Chemo Improves Progression-free Survival In Advanced Non-small Cell Lung Cancer: Study

For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS) compared with osimertinib alone, according to a study publishedonline Nov. 8 in the New England Journal of Medicine.

David Planchard, M.D., Ph.D., from Institut Gustave Roussy in Villejuif, France, and colleagues randomly assigned 557 patients with EGFR-mutated advanced NSCLC who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed plus either cisplatin or carboplatin) or to receive osimertinib monotherapy (80 mg once daily) in a 1:1 ratio.

The researchers found that investigator-assessed PFS was significantly longer in the osimertinib-chemotherapy group versus the osimertinib group. Overall, 57 and 41 percent of patients in the osimertinib-chemotherapy group and osimertintib group, respectively, were alive and progression-free at 24 months.

Consistent with the primary analysis, PFS as assessed according to blinded independent review was significantly longer in the combination group. An objective (complete or partial) response was observed in 83 and 76 percent of patients in the osimertinib-chemotherapy and osimertinib groups; median response duration was 24.0 and 15.3 months, respectively. The combination group had a higher incidence of grade 3 or higher adverse events from any cause than the monotherapy group.

"Osimertinib plus chemotherapy with pemetrexed and a platinum-based agent significantly improved progression-free survival as compared with osimertinib alone in the context of first-line treatment of patients with EGFR-mutated advanced NSCLC," the authors write.

Several authors disclosed ties to AstraZeneca, which manufactures osimertinib and funded the study.

More information: David Planchard et al, Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC, New England Journal of Medicine (2023). DOI: 10.1056/NEJMoa2306434

Yi-Long Wu et al, Combination Therapy for EGFR-Mutated Lung Cancer, New England Journal of Medicine (2023). DOI: 10.1056/NEJMe2311559

Copyright © 2023 HealthDay. All rights reserved.

Citation: Osimertinib + chemo improves progression-free survival in advanced non-small cell lung cancer: Study (2023, November 16) retrieved 22 November 2023 from https://medicalxpress.Com/news/2023-11-osimertinib-chemo-progression-free-survival-advanced.Html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.


Targeted Therapies In Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids On The Block

This Reading Room is a collaboration between MedPage Today® and:

Medpage Today Below is the abstract of the article.

Read the full article PDF by clicking here

or on the link below.

Purpose

With increased adoption of next-generation sequencing, tailored therapy on the basis of molecular status is being delivered for patients with early-stage resectable non–small-cell lung cancer (NSCLC). The purpose of this narrative review was to focus on recent developments of targeted therapies in the adjuvant and neoadjuvant/adjuvant setting for early-stage disease.

Methods

A systematic search of the MEDLINE/PubMed database was performed, focusing on studies published within the past 10 years. Our search queried "early-stage NSCLC (AND) tyrosine kinase inhibitor (TKI; OR) epidermal growth factor receptor (EGFR; OR) anaplastic lymphoma kinase (ALK)" and was limited only to prospective and ongoing studies.

Results

Most studies examining the benefit of targeted therapies in early-stage resectable NSCLC have been for EGFR-TKIs in the adjuvant setting. Currently, only one study, the ADAURA trial of adjuvant osimertinib, has demonstrated an overall survival benefit with the use of an EGFR-TKI in the adjuvant setting. Future work to build on the success of the ADAURA trial is focused on determining the optimal duration of targeted therapies and using biomarkers, such as circulating tumor DNA, to risk-stratify patients and guide maintenance targeted therapy duration.

Conclusion

The results of several ongoing studies are eagerly awaited regarding the use of targeted therapies in the neoadjuvant/adjuvant setting and for more uncommon or rare mutations such as ALK, ROS proto-oncogene 1, rearranged during transfection, mesenchymal-epithelial transition factor, and B-Raf proto-oncogene V600E. The treatment landscape for early-stage NSCLC harboring actionable mutations is likely to shift dramatically in the upcoming decade.

Read a Q&A about the review here and expert commentary about it here.

Read the full article

Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block

View and Download Article PDF




Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Mechanism and clinical progression of solid tumors bone marrow metastasis

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions